Literature DB >> 11420637

Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors.

M Pizzato1, O W Merten, E D Blair, Y Takeuchi.   

Abstract

To date, only adherent cell lines have been used for the generation of packaging cells for the production of type C retrovirus vectors. The large-scale production of high titre retrovirus vectors could benefit from the development of packaging cells growing in suspension. Here, we describe the ability of two different lymphoid cell lines, one B- and one T-lymphoblastoid cell line (Namalwa and CEM, respectively), to produce MLV-based vectors. Upon transfection with a third generation packaging construct, the virus particle production by Namalwa cells was characterised by low RT-activity, and by CEM cells as high RT activity as previously established adherent packaging cells. An amphotropic packaging cell line (CEMFLYA) was therefore established from CEM cells. Upon introduction of a lacZ vector genome, the novel packaging cell line produced vector particles routinely in the region of 10(7) infectious units/ml. The vectors were helper-free and highly stable in fresh human serum. The potential for scaled up vector production was demonstrated by continuous culture of the new packaging cells for 14 days in a 250 ml spinner flask. These suspension packaging cells should be applicable to large bioreactor systems to bulk produce high titre, complement-resistant retrovirus vectors for gene therapy.

Entities:  

Mesh:

Year:  2001        PMID: 11420637     DOI: 10.1038/sj.gt.3301457

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  4 in total

1.  Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.

Authors:  Steven A Feldman; Stephanie L Goff; Hui Xu; Mary A Black; James N Kochenderfer; Laura A Johnson; James C Yang; Qiong Wang; Maria R Parkhurst; Scott Cross; Richard A Morgan; Kenneth Cornetta; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2010-12-12       Impact factor: 5.695

Review 2.  Progress and challenges in viral vector manufacturing.

Authors:  Johannes C M van der Loo; J Fraser Wright
Journal:  Hum Mol Genet       Date:  2015-10-30       Impact factor: 6.150

3.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

4.  APOBEC3-mediated hypermutation of retroviral vectors produced from some retrovirus packaging cell lines.

Authors:  A D Miller; M J Metzger
Journal:  Gene Ther       Date:  2011-01-06       Impact factor: 5.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.